Frank C. Brosius, III, MD

Dr. Brosius' research focuses on identification of new targets for the treatment of diabetic kidney disease, the major cause of kidney failure in the world. One such target identified by him and his colleagues was the JAK/STAT signaling pathway. A recent clinical trial, co-led by Dr. Brosius, showed that a JAK inhibitor led to positive results in patients with diabetic kidney disease. He currently is a principal investigator on a National Institutes of Health R24 grant to identify additional targets for intervention in kidney, nerve and eye complications of diabetes. He has served on multiple committees and working groups related to his clinical and research interests with the Veterans Affairs Hospital, American Society of Nephrology, National Kidney Foundation, American Heart Association and American Diabetes Association.